EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy. Issue 2 (February 2018)

• Record Type: Journal Article
• Authors: Birch, David G.; Benz, Matthew S.; Miller, Daniel M.; Antoszyk, Andrew N.; Markoff, Joseph; Kozma, Petra; Meunier, Esmeralda; Sergott, Robert C.
• Is Part Of: Retina. Volume 38:Issue 2(2018)
• Publication Date: 2018-02
• Subjects: electroretinogram -- electroretinography -- ocriplasmin -- vitreomacular adhesion -- vitreomacular traction -- vitreoretinal disease -- laminin; Retina -- Diseases -- Periodicals; Retinal Diseases; Vitreous Body; 617.735
• DOI: 10.1097/IAE.0000000000001536
• Languages: English
• ISSNs: 0275-004X

Abstract

Abstract : Purpose: To explore a possible association between full-field electroretinograms with vitreomacular adhesion resolution and best-corrected visual acuity as part of the prospective, randomized, double-masked, sham-controlled Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) trial studying ocriplasmin. Methods: The ERG substudy enrolled 62 of 220 OASIS subjects (randomized 2:1) and analyzed full-field electroretinograms and their association with both vitreomacular adhesion resolution and best-corrected visual acuity from baseline through Month 24. Electroretinogram reductions were defined as acute full-field electroretinogram reductions in amplitude of ≥40% from baseline occurring at postinjection Day 7 or Day 28. Results: In the ocriplasmin group, 16/40 (40%) subjects developed ERG reductions, compared to 1/21 (4.8%) in the sham group; 13/16 (81.3%) and 1/1 (100%) resolved by study end, respectively. A total of 11/16 (68.8%) ocriplasmin-treated subjects with ERG reductions achieved vitreomacular adhesion resolution, compared to those without (9/24, 37.5%). The ocriplasmin-treated subjects with ERG reductions also gained more letters on average (11.3 vs. 9.3 letters) from baseline and had a difference of 6.7 letters in mean best-corrected visual acuity by study end compared to those without ERG reductions. Conclusion: Ocriplasmin-treated subjects with ERG reductions had a higher rate of vitreomacular adhesion resolution and showed better visual improvement than their counterparts without ERG reductions or sham subjects by study end. Abstract : The Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) trial electroretinogram substudy assessed a possible association between vitreomacular adhesion and best-corrected visual acuity with changes to full-field electroretinograms as part of a prospective, randomized, double-masked, sham-controlled clinical trial studying the efficacy and safety of ocriplasmin for the treatment of symptomatic vitreomacular adhesion.